Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 8/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557557 | 0.95 | HTR6 (0.40) | KDM4EALDH1A1HTR6TDP1LMNA | |
| SCHEMBL3560859 | 0.92 | KDM4E (0.39) | KDM4EALDH1A1HTR6TDP1LMNA | |
| SCHEMBL3555357 | 0.92 | HTR6 (0.45) | KDM4EALDH1A1HTR6TDP1LMNA | |
| SCHEMBL3562439 | 0.92 | HTR6 (0.45) | KDM4EALDH1A1HTR6TDP1MAPT | |
| SCHEMBL3566226 | 0.91 | KDM4E (0.36) | KDM4EALDH1A1HTR6TDP1MAPT | |
| SCHEMBL3563999 | 0.90 | HTR6 (0.37) | KDM4EALDH1A1HTR6LMNAMAPT | |
| SCHEMBL3561477 | 0.86 | AGTR1 (0.39) | KDM4EALDH1A1HTR6TDP1MAPT | |
| SCHEMBL3567118 | 0.85 | KDM4E (0.38) | KDM4EALDH1A1TDP1LMNAMAPT | |
| SCHEMBL3564344 | 0.84 | HTR6 (0.39) | KDM4EALDH1A1HTR6TDP1MAPT | |
| SCHEMBL3563804 | 0.84 | HTR6 (0.48) | HTR6LMNAMAPTPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | claimed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | claimed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | disclosed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | KDM4E 3751/4885ALDH1A1 1943/4885HTR6 56/4885 |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | KDM4E 3751/4885ALDH1A1 1943/4885HTR6 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.